534 related articles for article (PubMed ID: 30271665)
1. Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging.
Fournet M; Bonté F; Desmoulière A
Aging Dis; 2018 Oct; 9(5):880-900. PubMed ID: 30271665
[TBL] [Abstract][Full Text] [Related]
2. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
Yamagishi S; Taguchi K; Fukami K
Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
[TBL] [Abstract][Full Text] [Related]
3. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention.
Yamagishi S; Matsui T
Nutrition; 2016 Feb; 32(2):157-65. PubMed ID: 26602289
[TBL] [Abstract][Full Text] [Related]
4. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
5. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
6. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
[TBL] [Abstract][Full Text] [Related]
7. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.
Yamagishi S; Fukami K; Matsui T
Int J Cardiol; 2015 Apr; 185():263-8. PubMed ID: 25814214
[TBL] [Abstract][Full Text] [Related]
9. An overview on glycation: molecular mechanisms, impact on proteins, pathogenesis, and inhibition.
Uceda AB; Mariño L; Casasnovas R; Adrover M
Biophys Rev; 2024 Apr; 16(2):189-218. PubMed ID: 38737201
[TBL] [Abstract][Full Text] [Related]
10. Skin beautification with oral non-hydrolized versions of carnosine and carcinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging.
Babizhayev MA; Deyev AI; Savel'yeva EL; Lankin VZ; Yegorov YE
J Dermatolog Treat; 2012 Oct; 23(5):345-84. PubMed ID: 21756141
[TBL] [Abstract][Full Text] [Related]
11. [Glycation, glycoxidation and diabetes mellitus].
Boulanger E; Wautier JL; Dequiedt P; Schmidt AM
Nephrol Ther; 2006 Jan; 2 Suppl 1():S8-16. PubMed ID: 17378134
[TBL] [Abstract][Full Text] [Related]
12. Oxidative Stress and Advanced Lipoxidation and Glycation End Products (ALEs and AGEs) in Aging and Age-Related Diseases.
Moldogazieva NT; Mokhosoev IM; Mel'nikova TI; Porozov YB; Terentiev AA
Oxid Med Cell Longev; 2019; 2019():3085756. PubMed ID: 31485289
[TBL] [Abstract][Full Text] [Related]
13. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.
Yamagishi S
Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404
[TBL] [Abstract][Full Text] [Related]
14. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
Yamagishi S
Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix glycation and receptor for advanced glycation end-products activation: a missing piece in the puzzle of the association between diabetes and cancer.
Rojas A; Añazco C; González I; Araya P
Carcinogenesis; 2018 Apr; 39(4):515-521. PubMed ID: 29373651
[TBL] [Abstract][Full Text] [Related]
16. Photosensitized growth inhibition of cultured human skin cells: mechanism and suppression of oxidative stress from solar irradiation of glycated proteins.
Wondrak GT; Roberts MJ; Jacobson MK; Jacobson EL
J Invest Dermatol; 2002 Aug; 119(2):489-98. PubMed ID: 12190875
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of advanced glycation end products (Review).
Kuzan A
Biomed Rep; 2021 May; 14(5):46. PubMed ID: 33786175
[TBL] [Abstract][Full Text] [Related]
18. Endogenous alpha-oxoaldehydes and formation of protein and nucleotide advanced glycation endproducts in tissue damage.
Thornalley PJ
Novartis Found Symp; 2007; 285():229-43; discussion 243-6. PubMed ID: 17590998
[TBL] [Abstract][Full Text] [Related]
19. Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation.
Yamagishi SI; Sotokawauchi A; Matsui T
Mini Rev Med Chem; 2019; 19(13):1040-1048. PubMed ID: 30854960
[TBL] [Abstract][Full Text] [Related]
20. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins.
Fu S; Fu MX; Baynes JW; Thorpe SR; Dean RT
Biochem J; 1998 Feb; 330 ( Pt 1)(Pt 1):233-9. PubMed ID: 9461515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
